



A convenient and rapid approach for the synthesis of 1-benzyl-3-heterocyclic pyrazoles

Michael P. Curtis, Matthew F. Sammons, David W. Piotrowski*

Pfizer Global Research and Development, Groton/New London Laboratories, Pfizer Inc, Groton, CT 06340, United States

ARTICLE INFO

Article history:

Received 2 December 2008

Revised 10 July 2009

Accepted 13 July 2009

Available online 16 July 2009

ABSTRACT

A variety of 1-benzyl-3-heterocyclic pyrazoles were rapidly assembled by a two-step N-benylation/Suzuki coupling sequence. A one-pot variation of this sequence is demonstrated.

© 2009 Elsevier Ltd. All rights reserved.

1. Introduction

Regiocontrolled access to small, polar heterocycles has become an increasingly important part of a medicinal chemist's repertoire to examine structure–activity relationships (SARs) and adjust physicochemical properties of lead molecules. As part of a medicinal chemistry program, we were interested in rapidly evaluating an *N*-benzyl-3-heterocyclic pyrazole lead compound. Recently, methods to access (het)aryl-substituted imidazoles and pyrazoles via the corresponding boronic acids or esters have been published.^{1,2} Herein, we disclose a method to rapidly prepare 1-benzyl-3-heterocyclic pyrazole analogs (**1**) derived from commercially available 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1*H*-pyrazole (**2**) (see Fig. 1).

2. Results and discussion

In order to explore the SAR of a lead 3-(4-pyrimidinyl)pyrazole **1**, we wished to survey a range of *N*-substituents as well as a range of heterocycles at the 3-position. Initial exploration of the benzyl moiety of **1** while maintaining 4-pyrimidine constant at the 3-position was facilitated by the commercial availability of 1-(pyrimidin-4-yl)ethanone (**3**). Thus, **3** was treated with DMF-DMA in refluxing DMF to provide intermediate **4**.³ Subsequent ring closure with hydrazine hydrate in EtOH at room temperature afforded compound **5** in 75% yield. Benzylation of **5** was first accomplished using 4-chlorobenzyl bromide and Cs₂CO₃ in DMF. After aqueous work-up and flash chromatography, the reaction yielded two distinct regioisomers (**1a** and **6a**) in roughly 10:1 ratio (Scheme 1). NOESY analysis of the major isolate confirmed benzylation at the *N*-1 position. A strong correlation between the proton at the 5-po-

sition of the pyrazole ring and the two protons on the phenyl ring ortho to the carbon linker was observed upon irradiation of the methylene protons of the benzyl group.⁴ Similar regioselectivity





Figure 1. *N*-Benzyl-3-heterocyclic pyrazoles.



Scheme 1. Reagents and conditions: (a) DMF-DMA, DMF, 150 °C 18 h, 87%; (b) hydrazine hydrate, EtOH, rt 18 h, 75%; (c) *R*-benzyl bromide Cs₂CO₃, MeCN, 80 °C 2 h.

* Corresponding author. Tel.: +1 860 686 0271; fax: +1 860 686 6627.
E-mail address: david.w.piotrowski@pfizer.com (D.W. Piotrowski).

Table 1
3-(4-Pyrimidinyl)-*N*-benzylpyrazoles obtained by benzylation of **5**.

Compd	R	% Yield
1a	4-Cl	48
1b	H	47
1c	3-Cl	41
1d	2-Cl	70
1e	3-CF ₃	43
1f	3-CH ₃	62

was also observed for the benzylation of other analogs. In addition, the chemical shift of the benzylic protons of **1** typically appeared 0.6 ppm upfield when compared to benzylic protons of **6**, and thus served as diagnostic protons for identification of the desired regioisomer.⁵


Simplification of the benzylation procedure by replacement of DMF with acetonitrile allowed for filtration, concentration and purification by chromatography. Using this methodology we were able to rapidly synthesize a variety of substituted benzyl analogs in moderate to good yields (Table 1, compounds **1a–f**).

A facile, parallel-enabled approach to altering the pyrazole 3-substituent that did not rely on the three-step method depicted in Scheme 1 was sought. However, few methods to make 3-heterocyclic pyrazoles are amenable to parallel synthesis.⁶ Thus, benzylation of **2** followed by Suzuki cross-coupling would allow for rapid generation of 3-heterocyclic pyrazole analogs. Early attempts to effect *N*-benzylation of **2** provided less than 10% of desired product **7** (R = H) after aqueous work-up and chromatography. Although these results were discouraging, we believed the reaction was progressing, and that the boronate-ester group of the pyrazole was undergoing protodeboronation⁷ or hydrolysis during aqueous work-up and/or silica gel purification. To better understand the fate of boronate **7**, the crude reaction mixture was filtered, concentrated and subjected to LC–MS, GC–MS, and NMR analysis. Reverse phase LC–MS showed only the boronic acid hydrolysis product of **7**. However, GC–MS and NMR analysis confirmed complete conversion of **2** into **7**, ca. 8% of the undesired regioisomer and a trace of protodeboronated product. To avoid this decomposition, the crude reaction products **7** were used directly in the Suzuki cross-coupling.

To our satisfaction, Suzuki reaction of crude **7** with 5-fluoro-2-chloropyrimidine gave the desired product **1g** in 22% yield over two steps. Although this yield was less than optimal, higher yields were achieved with more activated heterocycles. Most importantly, we now had a method to readily access heterocycles at the 3-position of the pyrazole core. This process was further optimized by preparing intermediate **7** on scale and using the crude boronate ester for a series of Suzuki reactions. With this in place, a number of 3-heterocyclic pyrazole analogs were synthesized in parallel (Table 2, compounds **1g–r**).


We believed that this pyrazole benzylation/Suzuki coupling approach to compounds **1** could be simplified even further if both steps were carried out in a one-pot reaction sequence. Indeed, it was found that compounds **1** could be prepared directly from **2** in one pot through initial benzylation of **1** in the presence of excess Cs₂CO₃ followed by addition of 5 mol% Pd(PPh₃)₄ and aryl halide (Table 3).

In conclusion, we have described a rapid and convenient method to prepare 1-benzyl-3-heterocyclic pyrazole analogs (**1**) derived from commercially available 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1*H*-pyrazole (**2**). This two-step sequence is amenable to a one-pot synthesis, allowing for variation of substituents at two positions of the pyrazole and rapid examination of the series SAR.

Table 2
3-Heteroaryl-*N*-benzylpyrazoles obtained by Suzuki coupling of crude **7**

Compd	Het	R	X	% Yield
1g		H	Cl	22
1h	2-Pyrimidinyl	3-CF ₃	Br	28
1i		3-CF ₃	Cl	44
1j		3-CF ₃	Cl	43
1k		3-CF ₃	Cl	51
1l	2-Pyridazinyl	3-CF ₃	Cl	41
1m	phenyl	3-CF ₃	Br	48
1n		3-CF ₃	Br	50
1o		3-CF ₃	Cl	51
1p		3-CF ₃	Br	20
1q	2-Thiazolyl	3-CF ₃	Br	22
1r	2-Furyl	3-CF ₃	Br	35

Conditions: (a) R-benzyl bromide, Cs₂CO₃, MeCN, 80 °C 2 h; (b) Het-X, Pd(PPh₃)₄ Na₂CO₃, *i*PrOH/toluene/H₂O, 80 °C 18 h.

Table 3
3-Heteroaryl-*N*-benzylpyrazoles obtained by one-pot alkylation/Suzuki coupling of boronate ester **2**

Compd	Het	R	% Yield
1a	4-Pyrimidinyl	4-Cl	47
1c	4-Pyrimidinyl	3-Cl	43
1d	4-Pyrimidinyl	2-Cl	49
1s	2-Pyridinyl	4-Cl	36
1t	2-Pyridinyl	2-Cl	27

Conditions: (a) (i) R-benzyl bromide, Cs₂CO₃ (3 equiv), MeCN, 80 °C 2 h; (ii) heterocyclic-Cl, Pd(PPh₃)₄, H₂O, 80 °C 18 h.

3. Experimental

3.1. Typical experimental procedure for preparation and Suzuki coupling of 7

To a solution of 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (1.0 g, 5.1 mmol) in acetonitrile (35 mL) were added 3-(trifluoromethyl)benzyl bromide (1.23 g, 5.2 mmol) and cesium carbonate (2.5 g, 7.7 mmol). The reaction mixture was heated at 80 °C for 2 h. The reaction mixture was cooled, filtered, and concentrated to provide **7** as a yellow solid. To a solution of crude **7** (125 mg, 0.36 mmol) in toluene/*i*PrOH/water (7 mL) were added 2-chlorobenzothiazole (61 mg, 0.36 mmol), Pd(PPh₃)₄ (21 mg, 0.018 mmol), and sodium carbonate (95 mg, 0.9 mmol). The reaction mixture was heated at 80 °C for 18 h. After cooling to room temperature, the mixture was concentrated and purified using flash chromatography, eluting from 10:90 EtOAc/heptane to 50:50 EtOAc/heptane affording **1o** (65 mg, 51 %) as a colorless solid. ¹H NMR (CDCl₃, 400 MHz) δ 5.45 (s, 2H), 7.05 (d, *J* = 2.4 Hz, 1H), 7.37 (t, *J* = 7.2 Hz, 1H), 7.42–7.50 (m, 4H), 7.54 (s, 1H), 7.58, (d, *J* = 4.0 Hz, 1H), 7.89 (d, *J* = 8.0 Hz, 1H), 8.06 (d, *J* = 8.4, 1H); ¹³C NMR (CDCl₃, 100.51 MHz) δ 56.13, 106.13, 121.89, 123.20, 124.66, 125.51, 126.44, 129.75, 131.23, 131.59, 134.60, 137.04, 147.30, 153.90, 161.97 ppm; *m/z* (CI) 360 ([M+H]⁺, 100%); Anal. Calcd for C₁₈H₁₂F₃N₃S: C, 60.16; H, 3.37; N, 11.69. Found: C, 59.94; H, 3.04; N, 11.56.

3.2. Typical experimental procedure for the one-pot benzylation/Suzuki coupling of 2

To a suspension of 3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-pyrazole (50 mg, 0.26 mmol) and Cs₂CO₃ (273 mg,

0.77 mmol) in acetonitrile (2 mL) was added 4-chlorobenzyl bromide (53 mg, 0.26 mmol). The reaction mixture was heated at 80 °C for 2 h. Pd(PPh₃)₄ (15 mg, 0.013 mmol), 2-chloropyridine (25 μL, 0.27 mmol), and 50 μL water were added. The reaction mixture was stirred at 80 °C for 18 h. After cooling to room temperature, the mixture was filtered through Celite and concentrated. Purification by flash chromatography eluting with a 0–50% EtOAc in heptane gradient gave **1s** (25 mg, 36%) as a colorless solid. ¹H NMR (CDCl₃, 400 MHz) δ 5.34 (s, 2H) 6.89 (d, *J* = 2.35 Hz, 1H) 7.15–7.21 (m, 3H) 7.27–7.33 (m, 2H) 7.39 (d, *J* = 2.35 Hz, 1H) 7.69 (m, 1H) 7.86–7.96 (m, 1H) 8.58–8.65 (m, 1H); *m/z* (CI) 270 ([M+H]⁺, 100%).

References and notes

- McLaughlin, M.; Marcantonio, K.; Chen, C.; Davies, I. W. *J. Org. Chem.* **2008**, *73*, 4309.
- Primas, N.; Mahatsekake, C.; Bouillon, A.; Lancelot, J.-C.; Sopková-de Oliveira Santos, J.; Lohier, J.-F.; Rault, S. *Tetrahedron* **2008**, *64*, 4596.
- Wang, L.; Woods, K. W.; Li, Q.; Barr, K. J.; McCroskey, R. W.; Hannick, S. M.; Gherke, L.; Credo, R. B.; Hui, Y.; Marsh, K.; Warner, R.; Lee, J. Y.; Zielinski-Mozng, N.; Frost, D.; Rosenberg, S.; Sham, H. L. *J. Med. Chem.* **2002**, *45*, 1697.
- Price, S.; Bordogna, W.; Bull, R. J.; Clark, D. E.; Crackett, P. H.; Dyke, H. J.; Gill, M.; Harris, N. V.; Gorski, J.; Lloyd, J.; Lockey, P. M.; Mullett, J.; Roach, A. G.; Rousset, F.; White, A. B. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 370.
- The benzylic protons for **1a** = δ 5.37 ppm and **6a** = δ 6.01 ppm; **1b** = 5.40 ppm and **6b** = δ 6.05 ppm; **1e** = δ 5.46 ppm; **1g** = δ 5.45 ppm; **1i** = δ 5.47 ppm.
- (a) Patel, M.; Bachelier, L. T.; Rayner, M. M.; Cordova, B. C.; Klabe, R. M.; Erickson-Viitanen, S.; Seitz, S. P. *Bioorg. Med. Chem. Lett.* **1998**, *8*, 823; (b) Pavlik, W.; Kurzweil, E. M. *J. Heterocycl. Chem.* **1992**, *29*, 1357; (c) Balle, T.; Perregaard, J.; Ramirez, M. T.; Larsen, A. K.; SØby, K. K.; Liljefors, T.; Andersen, K. *J. Med. Chem.* **2003**, *46*, 265.
- (a) Campeau, L.; Fagnou, K. *Chem. Soc. Rev.* **2007**, *36*, 1058; (b) Tyrrell, E.; Brookes, P. *Synthesis* **2003**, 469.